Firefly Neuroscience shares rise 52.08% in intraday after partnering with US DoD to deploy AI-driven EEG platform for military mental health.

Firefly Neuroscience surged 52.08% in intraday trading, driven by an announcement that the company has entered a public-private partnership with the U.S. Department of War to deploy its FDA 510k-approved AI-driven EEG/ERP technology platform for assessing and treating PTSD and TBI in active duty personnel and veterans, expanding its commercial footprint into the U.S. government and defense health sectors.